Langmuir V K, Atcher R W, Hines J J, Brechbiel M W
Chemistry Division, Argonne National Laboratory, Illinois.
J Nucl Med. 1990 Sep;31(9):1527-33.
Alpha emitter-labeled antibodies (Abs) are of considerable interest in cancer therapy. Alpha particles are densely ionizing and therefore have a high radiobiologic effectiveness, and the cell killing produced is influenced very little by dose rate or hypoxic conditions. LS174T human colon adenocarcinoma spheroids were used in this study to evaluate the efficacy of alpha emitter-labeled Abs in a three-dimensional model. NRLU-10, an IgG2b Ab to a pancarcinoma antigen, and its Fab fragment were used. Initial kinetic studies using 125I-NRLU-10 revealed that a large number of binding sites/cell and high Ab affinity led to slow Ab penetration. This effect could be overcome by increasing the Ab concentration ten-fold for Fab but not for intact Ab. Bismuth-212-NRLU-10 therapy was very effective in killing single cells (over 3 log reduction in surviving fraction) but was ineffective in spheroids (less than 1 log reduction). This was likely due to inadequate penetration into the spheroids before the 212Bi decayed. The use of higher Ab concentrations, tumors with fewer antigenic sites/cell for the Ab being used, lower affinity Abs, alpha emitters with longer half-lives, and pretargeting with bifunctional Ab are all potential ways of increasing the efficacy of alpha emitter-labeled Abs for cancer therapy.
α发射体标记的抗体在癌症治疗中备受关注。α粒子具有密集的电离作用,因此具有较高的放射生物学效能,并且产生的细胞杀伤作用受剂量率或缺氧条件的影响很小。本研究使用LS174T人结肠腺癌球体在三维模型中评估α发射体标记抗体的疗效。使用了针对一种泛癌抗原的IgG2b抗体NRLU-10及其Fab片段。使用125I-NRLU-10进行的初步动力学研究表明,大量的结合位点/细胞和高抗体亲和力导致抗体渗透缓慢。对于Fab片段,将抗体浓度提高10倍可以克服这种效应,但对于完整抗体则不行。铋-212-NRLU-10疗法在杀死单细胞方面非常有效(存活分数降低超过3个对数),但在球体中无效(降低不到1个对数)。这可能是由于在212Bi衰变之前,其对球体的渗透不足。使用更高的抗体浓度、所用抗体的每个细胞抗原位点较少的肿瘤、低亲和力抗体、半衰期较长的α发射体以及用双功能抗体进行预靶向,都是提高α发射体标记抗体癌症治疗疗效的潜在方法。